Time: April 22, 2016 10:30-11:30 PM.

Venue: Shanghai World Expo Exhibition and Convention Center, Shanghai Municipal Science and Technology Commission, Eastern National Technology Transfer Center, Forum Area

 Backgrounder.

Science magazine ranked tumor immunotherapy as the top 10 scientific breakthroughs of 2013, while the official blog of the American Association for Cancer Research (AACR) published an article on December 21, 2015, that identified tumor immunotherapy as the most interesting direction in healthcare in 2015. In 2015 alone, the U.S. Food and Drug Administration (FDA) reportedly approved five drugs related to tumor immunotherapy, including the first immunotherapy drug for lung cancer and for childhood cancer. News of clinical trial progress, corporate partnerships, mergers and acquisitions, and funding for tumor immunotherapies is rife, and popular targets such as CTLA-4, PD-1, and PD-L1 are also frequently mentioned in industry media.

The results of marketed immunotherapies for cancer are encouraging, and new immunotherapies continue to be developed to better understand why they work in some patients and not in others, how they can be extended to other types of tumors, and how they can be enhanced in combination with other cancer therapies (e.g., tumor-targeted antibodies, radiation, chemotherapy, etc.). efficacy of therapies, these studies will certainly influence our treatment of cancer in the future.

Presentation Summary.

The event will examine the technological development of tumor immunotherapy from the perspective of intellectual property rights, especially patents, and identify the latest directions and trends in innovative activities, as well as the patent layouts of tumor immunotherapy invention teams and companies, both domestic and foreign, in the field of tumor immunotherapy in light of mergers and acquisitions and patent litigation.

For the PD-1/PD-L1 signaling pathway inhibitors segment, a detailed understanding of the patent layouts, patent litigation disputes, and future R&D directions of the leading companies in the industry provides information and guidance for other companies in the field or companies preparing to enter the field.

1. the research direction and IP status of the entire tumor immunotherapy field.

2. the patent layouts around PD-1 antibody drugs and the patent battles between Merton and Bristol-Myers Squibb regarding PD-1 antibody drugs.

3. the recent M&A actions between Mersal and Bristol-Myers Squibb around PD-1 antibody drug development, and the significance of the M&A actions from an IP layout perspective.

 Guest Speaker.

Dr. Winston Zhang, Patent Attorney / Lawyer Dr. Winston Zhang, co-founder of TiPLab, graduated from the Department of Biological Sciences and Technology at Tsinghua University. He then studied molecular regulation of genes with Prof. Markus Noll at the University of Zurich, Switzerland, and received his PhD in Molecular Biology. In addition, Dr. Zhang has in-depth knowledge of IP protection strategies in China, the United States and Europe. He holds a Master's degree in IP from ETH Zurich and has led the IP management teams of several well-known law firms and patent agencies in China and abroad, and has helped many companies in the biopharmaceutical industry to develop IP protection strategies that are closely integrated with their business plans.

Professionals from investment institutions, healthcare companies, universities and research institutes are cordially invited to participate in the interaction and exchange.

PS: On the day of the conference, please present your business card in exchange for an entrance badge.